Dipeptide Ingredients TRIZ Cases

SMAC-derived peptides displace IAP from caspases, restoring apoptosis and overcoming chemotherapy resistance.

Fragmented water diluent boosts permeability, allowing glycine agents to neutralize odors without increasing surfactant toxicity.

A proteasome inhibitor targets the 20s beta5 subunit to treat ovarian clear cell carcinoma.

Combining HuLuc63 with bortezomib overcomes chemotherapy relapse by reducing tumor mass and improving long-term survival.

Ionizing radiation sterilizes dry solid S-nitrosothiols without reducing purity, overcoming degradation limits of conventional methods.

Combination therapies treat hepatitis C virus infections using specific compound pairs to reduce viral load.

PMI5011 regulates DUB activity in cancer cells without affecting viability, addressing heterogeneity and resistance challenges.

PSMA-targeting conjugates deliver therapeutic agents to prostate cancer cells, sparing non-target tissues from harmful side effects.

Oyster-derived peptide inhibits angiotensin converting enzyme activity, resolving stability and side effect trade-offs in cardiovascular treatments.

Combining calcineurin inhibitors and glucocorticoids with viral vectors suppresses neutralizing antibodies to improve transgene expression in gene therapy.

Oral Alanyl-Glutamine formulations protect non-cancerous cells from chemotherapy toxicity, enabling full therapeutic dosing.

Cyclic urea compounds selectively inhibit Granzyme B through localized active site interactions.

Engineered antibodies with specific cysteine residues enable site-specific conjugation for homogeneous antibody-drug profiles.

Modified peptidomimetic compounds inhibit viral protease, addressing the lack of approved antiviral treatments for norovirus.

Merges Bcl-2 inhibition with chemotherapy to inhibit tumor growth while managing toxicity and resistance barriers in cancer treatment.

Proteasome inhibitors deplete plasma cells to lower antibody titers, preventing immune interference with protein replacement therapy.

Macrocyclic Kriptofix compounds selectively bind strontium, lead, and tin ions while preserving essential calcium and magnesium levels.

A nutraceutical gummy composition delivers dihydromyricetin and electrolytes to counteract alcohol effects.

Combining yucca schidigera, quillaja saponaria, and antimicrobials reduces coccidian oocysts while maintaining productivity.

Formula I compounds inhibit hepatitis C virus replication via protease blockade, replacing injectable interferon with an oral treatment.

Hemoglobin conjugates deliver oxygen and cytotoxins to hypoxic tumors, reducing systemic toxicity while inhibiting tumor growth.

Targeting PI3K/AKT/mTOR and RAS/RAF/MAPK pathways with proteasome inhibitors and omipalisib addresses incomplete therapeutic responses in current treatments.

Antimicrobial material with an efflux pump inhibitor overcomes antibiotic resistance by blocking microbial pumps to accumulate toxic solvent levels.

Segmenting oxidative stress assessment into multiple distinct biomarker measurements improves accuracy while maintaining operational simplicity.

Oral muramyl peptides resolve skeletal growth retardation by stimulating IGF-1 production to increase bone length.

FRET-based enzymatic assays enable high-throughput screening of small molecule inhibitors targeting SARS-CoV-2 Mpro, accelerating drug discovery timelines.

Targeted NS5A inhibitors resolve the trade-off between antiviral efficacy and host cell toxicity in chronic hepatitis C treatment.

A thermogenic composition induces heat production through molecular activation.

Combining lidocaine, L-carnosine and dexpanthenol resolves the trade-off between immediate pain relief and sustained healing for oral mucositis.

Emetine targets ribosomal protein 14 to inhibit viral replication, reducing side effects and resistance associated with conventional therapies.

Combining roneparstat with melphalan overcomes resistance and decreases tumor burden in relapsed multiple myeloma.

Novel sulfur compounds inhibit hepatitis C virus NS3/NS4a serine protease activity through direct enzymatic binding.

Molecular docking of 400 dipeptides identifies high-activity candidates, addressing low accuracy in current short peptide research.

Heating biomolecules in a vacuum chamber enables uniform coating while preserving biological properties damaged by harsh conditions.

ADAM10 inhibitors block alpha-hemolysin binding to prevent epithelial disruption and cytotoxicity during Staphylococcal infections.

Combining HPTP-beta inhibitors with anti-VEGF agents stabilizes ocular vasculature against disease progression.

Combining plitidepsin with other antiviral agents addresses insufficient single-agent efficacy by targeting multiple viral processes simultaneously.

Hydrophilic antibody-drug conjugates maintain favorable pharmacokinetic profiles despite high drug loadings that typically increase clearance rates.

A subcutaneous anti-CD38 antibody composition utilizes recombinant human hyaluronidase to facilitate tissue absorption and distribution.

Combining EGFR and NF-kB antagonists overcomes acquired resistance to cetuximab by inhibiting Snail-induced epithelial-mesenchymal transition.

LTX-109 tripeptides target non-enveloped viruses through electrostatic attraction, bypassing resistance mechanisms common with conventional antivirals.

Inhibiting IL-36 proteolytic processing with neutrophil-derived protease blockers reduces severe psoriasis inflammation by preventing cytokine activation.

Anti-CD30 antibody-drug conjugates deplete HIV reservoirs in CD30-positive cells, restoring CD4+ T-cell counts.